Sinclair Pharma plc
(the "Company")
Annual Information Update
26 November 2009, Godalming, UK: Sinclair Pharma Plc,the international specialty
pharma company, is pleased to provide an annual information update in
accordance with the requirements of Prospectus Rule 5.2.1R, of information that
has been published or made available to the public for the period from 16
November 2008 to date. The information referred to in this update was current
at the time the information was published but some information may now be out
of date.
1. Announcements made via a Regulatory Information Service
The Company made the following regulatory announcements via the Regulatory News
Service on or around the dates indicated:
Date Announcement
24/11/2009 Publication of Prospectus
23/11/2009 Jerry Randall to step down as CFO
19/11/2009 Interim Management Statement
12/11/2009 Sinclair, Orapharma terminate US Decapinol agreement
11/11/2009 Result of General Meeting
02/11/2009 Annual Report & Accounts
29/10/2009 New Debt Facility
12/10/2009 Acquisition of Flammazine and Flammacerium from Solvay
12/10/2009 Preliminary results for the year ended 30 June 2009
05/10/2009 Re-Convertible Unsecured Loan Note
23/09/2009 Re-Convertible Unsecured Loan Note
23/09/2009 INVESCO Limited Rule 8.3 - Sinclair Pharma plc
22/09/2009 Statement re Share Price Movement
14/09/2009 Second Price Monitoring Extension
14/09/2009 Price Monitoring Extension
07/09/2009 Placement of Convertible Unsecured Loan Notes
28/08/2009 Total Voting Rights
17/08/2009 Blocklisting Interim Review
04/08/2009 Sebclair launched in US
22/07/2009 Trading update for the year ending 30 June 2009
15/06/2009 Holding(s) in Company
18/05/2009 Interim Management Statement
22/04/2009 Change of Adviser
18/03/2009 Second Price Monitoring Extension
18/03/2009 Price Monitoring Extension
03/03/2009 Change of Adviser
26/02/2009 Interim Results
20/02/2009 Sinclair Pharma signs agreements with BMG Pharma
13/02/2009 Notice of Results
09/02/2009 Blocklisting Interim Review
05/02/2009 Holding(s) in Company
04/02/2009 Sinclair strengthens European sales and marketing
23/01/2009 Holding(s) in Company
07/01/2009 Agreement signed with Graceway for Atopiclair in US
31/12/2008 Total Voting Rights
22/12/2008 Sinclair Pharma announces sales collaboration
12/12/2008 Director/PDMR Shareholding
11/12/2008 Grant of Share Awards under Long-term Incentive Plan
08/12/2008 Result of AGM
08/12/2008 Placing
28/11/2008 Total Voting Rights
20/11/2008 Annual Information Update
18/11/2008 Additional Listing
2. Documents filed at Companies House
Type Date Description
MG02 25/11/2009 Declaration of satisfaction in full or in
part of a mortgage or charge
MG02 25/11/2009 Declaration of satisfaction in full or in
part of a mortgage or charge
88(2) 14/09/2009 Issue of 9,189 ordinary 1p shares at 1p
each on 30 June 2009
88(2) 06/03/2009 Issue of 7,000,000 ordinary 1p shares at
16p each on 8 December 2008
88(2) 06/03/2009 Issue of 1,956,521 ordinary 1p shares at
23p each on 12 November 2008
88(2) 02/03/2009 Capitals not rolled up
88(2) 23/01/2009 Issue of 400,000 ordinary 1p shares at 23p
each on 18 November 2008
363a 19/12/2008 Annual Return
AA 17/12/2008 Group of companies accounts made up to 30
June 2008
288b 10/12/2008 Resignation of Ralph Steven Harris as a
director
RES10 10/12/2008 Authorised allotment of shares and
debentures
RES01 10/12/2008 Alteration to memorandum and articles
RES09 10/12/2008 Authority - purchase shares other than from
capital
RES11 10/12/2008 Disapplication of pre-emption rights
Copies of documents filed at Companies House can be obtained from the Companies
House website at www.companieshouse.gov.uk or Companies House, Crown Way,
Cardiff F14 3UZ.
3. Additional Documents
The Company submitted copies of the following documents to the UK Listing
Authority, which have also been provided to shareholders:
Date Document
24/11/2009 Prospectus in connection with the acquisition of the
Solvay Products, firm placing and placing and open offer
of 56,731,322 new ordinary shares at 32 pence per new
ordinary share and Notice of General Meeting
02/11/2009 Annual report and accounts for the year ended 30 June
2008 and Notice of Annual General Meeting
26/02/2009 Interim report for the six months to 31 December 2008
All of the documents listed above can be obtained from the Company's website
www.sinclairpharmair.com and are available for inspection at the UK Listing
Authority's Document Viewing Facility, which is situated at The Financial
Services Authority, 25, The North Colonnade, Canary Wharf, London E14 5HS.
- Ends -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Dr Michael Flynn, CEO
Jerry Randall, CFO
Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500
Shaun Dobson
Claes Spång
Capital MS&L Tel +44 (0)20 7307 5340
Mary Clark
Anna Mitchell
Notes to Editors:
About Sinclair Pharma Plc: www.sinclairpharma.com.
Sinclair Pharma plc is an international specialty pharmaceutical company
providing solutions to treat dermatological, oral care and gynaecological
diseases through advanced surface technology and innovative delivery
systems. It has a growing sales and marketing operation that is already present
in France, Italy and Spain, and a complementary marketing partner network that
spans more than 90 countries.
This annual information update is required by, and is being made pursuant to,
Article 10 of the Prospectus Directive as implemented in the UK by Prospectus
Rule 5.2 and not for any other purpose and neither the Company, nor any other
person, takes any responsibility for, or makes any representation, express or
implied, as to the accuracy or completeness of, the information which it
contains. The information is not necessarily up to date as at the date of this
annual information update and the Company does not undertake any obligation to
update any such information in the future. Further, such information may have
been prepared in accordance with the laws or regulations of a particular
jurisdiction and may not comply with or meet the relevant standards of
disclosure in any other jurisdiction. Neither this annual information update,
nor the information referred to in it, constitutes, by virtue of this
communication, an offer of any securities addressed to any person and it should
not be relied on by any person.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act
of 1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995. Actual results of events could differ materially from those described in
the forward-looking statements due to a variety of factors.
END
SINCLAIR PHARMA PLC
